% Success for new drugs in pharma industry
Note: The R&D success percentages in this article are based on aggregate industry data from the IQVIA Institute’s 2026 Global Trends Report and historical benchmarks from Nature Reviews Drug Discovery. While specific companies like Eli Lilly or Novo Nordisk may beat these averages due to their expertise in metabolic health, the industry-wide "Probability of Success" from Phase I to FDA approval remains roughly 10-14%.